In a world still letting tech nibble around the edges of healthcare, Scopio Labs just pushed a $10 million extension into their Series D like a scalpel through red tape, and this one cuts clean.
This isn’t another glorified microscope startup waving AI pom-poms. Scopio Labs, founded by Itai Hayut (CEO, applied physics PhD, ex-optics guy who could probably build a telescope out of a stapler) and Erez Na’aman (CTO, deep learning and computational photography savant who sees cell structures like Neo sees the Matrix), has been quietly doing the hard thing: turning hematology’s most manual, analog bottleneck, peripheral blood smear (PBS) analysis, into a high-res, full-field, AI-driven digital process. Not a slice of the slide. The whole damn thing.
Their FDA-cleared platform is now deployed in clinical labs across the U.S. and Europe, diagnosing tens of thousands of cells at once with accuracy and speed that laughs in the face of legacy workflows. With CE marking secured and regulatory boxes checked like it’s a sport, they’re not tiptoeing around compliance, they’re making it a competitive edge.
The $10 million extension, led by Viola Growth (shoutout Igal Shany, watching this market with sniper precision), joins the $42 million raised in last year’s initial Series D led by Fortissimo Capital (salute to Yuval Cohen, who’s been backing bold since before it was fashionable). Add repeat investors like Aurum Ventures, OurCrowd, Ilex Medical, LR Group, and OTV, and it’s clear: the smart money isn’t just in the room, it’s doubling down.
Scopio’s custom optics, deep learning inference engine, and full-slide analyzers (shoutout to their X100 and X100 HT systems) are now being backed by global commercial scaling, Siemens Healthineers distribution, and product expansion into bone marrow aspirates and AI-powered morphology biomarkers. Their Complete Blood Morphology (CBM) analyzer isn’t just a tool, it’s a full-blown data-generating machine, turning routine smears into rich diagnostic intelligence.
Now with ~150 employees across Tel Aviv, Parsippany, and beyond, they’re scaling up: sales, support, and a roadmap packed with longitudinal monitoring tools, all designed to break hematology out of the 1980s and into the next diagnostic era. Headcount’s climbing 30% by Q2 2026, because you don’t build an empire on autopilot.
